ArticleF&S reports2025
Assisted sperm fusion insemination improves fertilization rates and increases usable embryos for transfer: a clinical sibling-oocyte study.
Article in F&S reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protocol for assisted sperm fusion insemination of human oocytes using zona pellucida-bound sperm.STAR protocols · 2026Article
- Reply of the authors: Assisted sperm fusion insemination improves fertilization rates and increases usable embryos for transfer: a clinical sibling-oocyte study.F&S reports · 2025Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the impact of assisted sperm fusion insemination (ASFI), a microinsemination method using sperm bound to the zona pellucida (ZP-sperm) without penetrating the oocyte membrane, compared with conventional intracytoplasmic sperm injection (C-ICSI), on fertilization and embryonic development. Design: Prospective clinical sibling-oocyte study. Subjects: A total of 197 oocytes from 24 patients who underwent 35 oocyte retrieval cycles from January 2023 to April 2024 were analyzed. Patients who underwent retrieval of both, at least 2 metaphase II (MII) oocytes and at least 1 immature or degenerated oocyte, were recruited. Intervention: Metaphase II oocytes were alternately allocated to 2 groups: ASFI and C-ICSI groups. To obtain ZP-sperm for ASFI, immature or degenerated oocytes were incubated with 10,000 motile sperm for 3 hours. After harvesting the ZP-sperm, it was pressed onto the membrane of an MII oocyte for 10 seconds in the ASFI group. Conventional intracytoplasmic sperm injection was performed conventionally in the C-ICSI group. Main Outcome Measures: The rates of 2 pronuclei (2PN), degeneration, blastocyst formation, and usable embryos, defined as the total number of transferred or cryopreserved embryos divided by the number of MII oocytes, were compared between the 2 groups. Results: The 2PN rate of the ASFI group was 88.0% (73/83), which was significantly higher than that of the C-ICSI group (70.2% [80/114]). In addition, a significantly lower degeneration rate was observed in the ASFI group (0% [0/83]) than in the C-ICSI group (8.8% [10/114]). The blastocyst formation rate was equivalent in the 2 groups (ASFI group, 63.9% [39/61]; C-ICSI group, 62.0% [44/71]). However, the usable embryo rate was significantly higher in the ASFI group (45.8% [38/83]) than in the C-ICSI group (28.1% [32/114]). Conclusion: The ASFI group yielded significantly higher 2PN and lower degeneration rates than the C-ICSI group. Consequently, the ASFI group experienced a higher number of embryos usable for implantation, although there was no significant difference in the blastocyst formation rate between the 2 groups. Further studies with a larger number of cases will be needed for more general application of these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.